DaVita Inc. (NYSE:DVA) Shares Purchased by Handelsbanken Fonder AB

Handelsbanken Fonder AB boosted its stake in shares of DaVita Inc. (NYSE:DVA) by 108.8% during the 4th quarter, Holdings Channel.com reports. The firm owned 16,700 shares of the company’s stock after purchasing an additional 8,700 shares during the quarter. Handelsbanken Fonder AB’s holdings in DaVita were worth $1,749,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. CWM LLC grew its position in DaVita by 36.9% during the 4th quarter. CWM LLC now owns 1,537 shares of the company’s stock worth $161,000 after purchasing an additional 414 shares during the period. abrdn plc grew its position in shares of DaVita by 17.4% during the 4th quarter. abrdn plc now owns 168,316 shares of the company’s stock valued at $17,633,000 after acquiring an additional 24,966 shares during the period. Federated Hermes Inc. grew its position in shares of DaVita by 6,158.3% during the 4th quarter. Federated Hermes Inc. now owns 77,979 shares of the company’s stock valued at $8,169,000 after acquiring an additional 76,733 shares during the period. Daiwa Securities Group Inc. grew its position in shares of DaVita by 3.7% during the 4th quarter. Daiwa Securities Group Inc. now owns 4,802 shares of the company’s stock valued at $503,000 after acquiring an additional 171 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank grew its position in shares of DaVita by 28.5% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 95,657 shares of the company’s stock valued at $10,021,000 after acquiring an additional 21,205 shares during the period. 90.12% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

DVA has been the topic of a number of analyst reports. UBS Group raised their target price on DaVita from $113.00 to $134.00 and gave the company a “buy” rating in a research report on Wednesday, February 14th. Barclays began coverage on shares of DaVita in a research note on Wednesday, March 6th. They issued an “equal weight” rating and a $133.00 price target on the stock. Truist Financial raised their price target on shares of DaVita from $130.00 to $135.00 and gave the company a “hold” rating in a research note on Tuesday, February 20th. StockNews.com raised shares of DaVita from a “buy” rating to a “strong-buy” rating in a research note on Thursday. Finally, TheStreet raised shares of DaVita from a “c+” rating to a “b-” rating in a research note on Wednesday, February 7th. Two research analysts have rated the stock with a hold rating, one has given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $118.50.

DaVita Trading Up 0.6 %

DVA opened at $133.51 on Friday. The company has a debt-to-equity ratio of 6.65, a current ratio of 1.19 and a quick ratio of 1.13. The company’s 50 day simple moving average is $132.12 and its two-hundred day simple moving average is $110.60. DaVita Inc. has a 1-year low of $71.51 and a 1-year high of $141.54. The firm has a market capitalization of $11.71 billion, a price-to-earnings ratio of 18.04, a price-to-earnings-growth ratio of 1.19 and a beta of 1.04.

DaVita (NYSE:DVA) last released its earnings results on Tuesday, February 13th. The company reported $1.87 earnings per share for the quarter, topping analysts’ consensus estimates of $1.53 by $0.34. DaVita had a net margin of 5.70% and a return on equity of 64.42%. The business had revenue of $3.15 billion for the quarter, compared to analyst estimates of $3.01 billion. During the same period last year, the company posted $1.11 EPS. The business’s revenue was up 7.8% on a year-over-year basis. Analysts expect that DaVita Inc. will post 9.23 EPS for the current fiscal year.

Insiders Place Their Bets

In other DaVita news, CEO Javier Rodriguez sold 67,603 shares of the firm’s stock in a transaction that occurred on Monday, February 26th. The shares were sold at an average price of $126.11, for a total value of $8,525,414.33. Following the transaction, the chief executive officer now directly owns 488,697 shares of the company’s stock, valued at approximately $61,629,578.67. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In other news, CEO Javier Rodriguez sold 67,603 shares of the firm’s stock in a transaction that occurred on Monday, February 26th. The shares were sold at an average price of $126.11, for a total transaction of $8,525,414.33. Following the completion of the sale, the chief executive officer now owns 488,697 shares in the company, valued at approximately $61,629,578.67. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider James O. Hearty sold 26,164 shares of the firm’s stock in a transaction that occurred on Friday, February 16th. The stock was sold at an average price of $119.64, for a total transaction of $3,130,260.96. Following the sale, the insider now owns 20,264 shares of the company’s stock, valued at approximately $2,424,384.96. The disclosure for this sale can be found here. Insiders have sold 134,540 shares of company stock valued at $16,551,071 in the last ninety days. 1.40% of the stock is currently owned by corporate insiders.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.